The Filings Report

Merck

MRKNYSECIK 310158Healthcare / Drug Manufacturersfiscal year ends December73 quarters since 2008

Revenue, Q2 FY2026
$16.6B
+5.1% on Q2 FY2025
Net income
−$1.3B
−130.2% on Q2 FY2025
Free cash flow
$4.5B
+77.0% on Q2 FY2025
Diluted EPS
$-0.54
−130.7% on Q2 FY2025
Revenue, TTM
$66.6B
trailing four quarters
Net margin, TTM
4.8%
net income $3.2B
Free cash flow, TTM
$16.1B
$20.0B less $3.9B capex
Cash and equivalents
$6.8B
long-term debt $51.1B, Jun 30, 2026
Shares, 12-month change
−1.2%
2.47B shares, Jun 30, 2026
Buybacks, TTM
$4.2B
1.1% of market value
Dividends, TTM
$8.3B
2.3% of market value
Market value
$368.9B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 7, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Merck reported revenue of $16.6B, +5.1% on Q2 FY2025, and net loss of $1.3B (−130.2%). Free cash flow, operating cash flow less capital expenditures, was $4.5B ($5.4B less $893M). Diluted earnings per share were $-0.54.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 7, 2026.

Revenue and net incomeRevenueNet income
−$10B$0$10B$20BQ3'22, Revenue: $15.0BQ3'22, Net income: $3.2BQ3'22Q4'22, Revenue: $13.8BQ4'22, Net income: $3.0BQ4'22Q1'23, Revenue: $14.5BQ1'23, Net income: $2.8BQ1'23Q2'23, Revenue: $15.0BQ2'23, Net income: −$6.0BQ2'23Q3'23, Revenue: $16.0BQ3'23, Net income: $4.7BQ3'23Q4'23, Revenue: $14.6BQ4'23, Net income: −$1.2BQ4'23Q1'24, Revenue: $15.8BQ1'24, Net income: $4.8BQ1'24Q2'24, Revenue: $16.1BQ2'24, Net income: $5.5BQ2'24Q3'24, Revenue: $16.7BQ3'24, Net income: $3.2BQ3'24Q4'24, Revenue: $15.6BQ4'24, Net income: $3.7BQ4'24Q1'25, Revenue: $15.5BQ1'25, Net income: $5.1BQ1'25Q2'25, Revenue: $15.8BQ2'25, Net income: $4.4BQ2'25Q3'25, Revenue: $17.3BQ3'25, Net income: $5.8BQ3'25Q4'25, Revenue: $16.4BQ4'25, Net income: $3.0BQ4'25Q1'26, Revenue: $16.3BQ1'26, Net income: −$4.2BQ1'26Q2'26, Revenue: $16.6BQ2'26, Net income: −$1.3BQ2'26−$10B$0$10B$20BQ3'22, Revenue: $15.0BQ3'22, Net income: $3.2BQ4'22, Revenue: $13.8BQ4'22, Net income: $3.0BQ4'22Q1'23, Revenue: $14.5BQ1'23, Net income: $2.8BQ2'23, Revenue: $15.0BQ2'23, Net income: −$6.0BQ2'23Q3'23, Revenue: $16.0BQ3'23, Net income: $4.7BQ4'23, Revenue: $14.6BQ4'23, Net income: −$1.2BQ4'23Q1'24, Revenue: $15.8BQ1'24, Net income: $4.8BQ2'24, Revenue: $16.1BQ2'24, Net income: $5.5BQ2'24Q3'24, Revenue: $16.7BQ3'24, Net income: $3.2BQ4'24, Revenue: $15.6BQ4'24, Net income: $3.7BQ4'24Q1'25, Revenue: $15.5BQ1'25, Net income: $5.1BQ2'25, Revenue: $15.8BQ2'25, Net income: $4.4BQ2'25Q3'25, Revenue: $17.3BQ3'25, Net income: $5.8BQ4'25, Revenue: $16.4BQ4'25, Net income: $3.0BQ4'25Q1'26, Revenue: $16.3BQ1'26, Net income: −$4.2BQ2'26, Revenue: $16.6BQ2'26, Net income: −$1.3BQ2'26

Net income losses drawn in red.

Free cash flow
−$3B$0$3B$5B$8B$10BQ3'22, Free cash flow: $4.5BQ3'22Q4'22, Free cash flow: $3.3BQ4'22Q1'23, Free cash flow: $332MQ1'23Q2'23, Free cash flow: $2.7BQ2'23Q3'23, Free cash flow: $6.8BQ3'23Q4'23, Free cash flow: −$743MQ4'23Q1'24, Free cash flow: $2.2BQ1'24Q2'24, Free cash flow: $4.8BQ2'24Q3'24, Free cash flow: $8.5BQ3'24Q4'24, Free cash flow: $2.5BQ4'24Q1'25, Free cash flow: $1.2BQ1'25Q2'25, Free cash flow: $2.5BQ2'25Q3'25, Free cash flow: $6.8BQ3'25Q4'25, Free cash flow: $1.8BQ4'25Q1'26, Free cash flow: $2.9BQ1'26Q2'26, Free cash flow: $4.5BQ2'26−$3B$0$3B$5B$8B$10BQ3'22, Free cash flow: $4.5BQ4'22, Free cash flow: $3.3BQ4'22Q1'23, Free cash flow: $332MQ2'23, Free cash flow: $2.7BQ2'23Q3'23, Free cash flow: $6.8BQ4'23, Free cash flow: −$743MQ4'23Q1'24, Free cash flow: $2.2BQ2'24, Free cash flow: $4.8BQ2'24Q3'24, Free cash flow: $8.5BQ4'24, Free cash flow: $2.5BQ4'24Q1'25, Free cash flow: $1.2BQ2'25, Free cash flow: $2.5BQ2'25Q3'25, Free cash flow: $6.8BQ4'25, Free cash flow: $1.8BQ4'25Q1'26, Free cash flow: $2.9BQ2'26, Free cash flow: $4.5BQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$20B$40B$60BQ3'22, Cash and equivalents: $11.1BQ3'22, Long-term debt: $28.5BQ3'22Q4'22, Cash and equivalents: $12.7BQ4'22, Long-term debt: $28.7BQ4'22Q1'23, Cash and equivalents: $9.7BQ1'23, Long-term debt: $28.1BQ1'23Q2'23, Cash and equivalents: $5.7BQ2'23, Long-term debt: $34.1BQ2'23Q3'23, Cash and equivalents: $8.6BQ3'23, Long-term debt: $34.0BQ3'23Q4'23, Cash and equivalents: $6.8BQ4'23, Long-term debt: $33.7BQ4'23Q1'24, Cash and equivalents: $5.6BQ1'24, Long-term debt: $31.1BQ1'24Q2'24, Cash and equivalents: $11.3BQ2'24, Long-term debt: $34.7BQ2'24Q3'24, Cash and equivalents: $14.6BQ3'24, Long-term debt: $35.0BQ3'24Q4'24, Cash and equivalents: $13.2BQ4'24, Long-term debt: $34.5BQ4'24Q1'25, Cash and equivalents: $8.6BQ1'25, Long-term debt: $33.5BQ1'25Q2'25, Cash and equivalents: $8.0BQ2'25, Long-term debt: $34.0BQ2'25Q3'25, Cash and equivalents: $18.2BQ3'25, Long-term debt: $40.0BQ3'25Q4'25, Cash and equivalents: $14.6BQ4'25, Long-term debt: $46.8BQ4'25Q1'26, Cash and equivalents: $5.3BQ1'26, Long-term debt: $46.7BQ1'26Q2'26, Cash and equivalents: $6.8BQ2'26, Long-term debt: $51.1BQ2'26$0$20B$40B$60BQ3'22, Cash and equivalents: $11.1BQ3'22, Long-term debt: $28.5BQ4'22, Cash and equivalents: $12.7BQ4'22, Long-term debt: $28.7BQ4'22Q1'23, Cash and equivalents: $9.7BQ1'23, Long-term debt: $28.1BQ2'23, Cash and equivalents: $5.7BQ2'23, Long-term debt: $34.1BQ2'23Q3'23, Cash and equivalents: $8.6BQ3'23, Long-term debt: $34.0BQ4'23, Cash and equivalents: $6.8BQ4'23, Long-term debt: $33.7BQ4'23Q1'24, Cash and equivalents: $5.6BQ1'24, Long-term debt: $31.1BQ2'24, Cash and equivalents: $11.3BQ2'24, Long-term debt: $34.7BQ2'24Q3'24, Cash and equivalents: $14.6BQ3'24, Long-term debt: $35.0BQ4'24, Cash and equivalents: $13.2BQ4'24, Long-term debt: $34.5BQ4'24Q1'25, Cash and equivalents: $8.6BQ1'25, Long-term debt: $33.5BQ2'25, Cash and equivalents: $8.0BQ2'25, Long-term debt: $34.0BQ2'25Q3'25, Cash and equivalents: $18.2BQ3'25, Long-term debt: $40.0BQ4'25, Cash and equivalents: $14.6BQ4'25, Long-term debt: $46.8BQ4'25Q1'26, Cash and equivalents: $5.3BQ1'26, Long-term debt: $46.7BQ2'26, Cash and equivalents: $6.8BQ2'26, Long-term debt: $51.1BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 7, 2026.

Merck income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue16,60716,28616,40017,27615,80615,52915,62416,657+5.1%
Cost of revenue4,3954,1955,5513,8553,5573,4193,8284,080+23.6%
Gross profit—————————
Research and development9,74112,5923,8864,2344,0483,6214,5845,862+140.6%
Selling, general and administrative2,9042,7002,8982,6332,6492,5522,8642,731+9.6%
Operating income—————————
Other income (expense)(99)(138)(432)238735(127)162−1514.3%
Pretax income(683)(3,534)3,4206,7454,9995,9034,1704,090−113.7%
Income tax654709458958571818426929+14.5%
Net income(1,335)(4,240)2,9635,7854,4275,0793,7433,157−130.2%
Diluted EPS ($)(0.54)(1.72)—2.321.762.01—1.24−130.7%
Diluted shares (millions)2,4702,472—2,4982,5132,531—2,541—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 7, 2026.

Merck balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents6,8495,32714,56518,1698,0078,62913,24214,593−14.5%
Short-term investments2923750456155994470−52.5%
Total current assets36,67935,01543,51647,55737,06535,50338,78240,361−1.0%
Total assets129,802128,685136,866129,546117,523115,122117,106117,532+10.4%
Total current liabilities27,73126,94528,32728,62826,03725,17428,42029,586+6.5%
Long-term debt51,08146,67346,75039,96933,96833,48434,46234,982+50.4%
Total liabilities—————————
Stockholders’ equity41,93345,87852,60651,85048,99348,33546,31344,502−14.4%
Shares outstanding (millions)2,4672,4702,4722,4822,4982,5112,5262,530—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 7, 2026.

Merck cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow5,3703,9182,8577,8223,2932,5003,4509,291+63.1%
Capital expenditures8939911,0339877641,328937783+16.9%
Free cash flow (CFO − capex)4,4772,9271,8246,8352,5291,1722,5138,508+77.0%
Depreciation and amortization—————————
Share repurchases7578741,2521,3231,3451,164489444−43.7%
Dividends paid2,1442,1052,0182,0312,0772,0501,9511,953+3.2%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

Merck income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Mar 1, 2010FY2008ended Dec 31, 2008filed Jul 24, 2009FY2007ended Dec 31, 2007filed Jul 24, 2009
Revenue65,01164,16860,11559,28348,70441,51839,12142,29440,12239,807—————45,98727,42823,85024,198
Cost of revenue16,38215,19316,12617,41113,62613,61812,01613,50912,91214,030—————————
Gross profit———————————————————
Research and development15,78917,93830,53113,54812,24513,3979,7249,75210,33910,2616,7047,1807,5038,1688,46711,1115,8454,8054,883
Selling, general and administrative10,73310,81610,50410,0429,6348,9559,45510,10210,07410,01710,31311,60611,91112,77613,73313,1258,5437,3777,557
Operating income———————————————————
Other income (expense)(151)24(466)(1,501)1,341890(129)402500(189)(1,527)11,613(411)(1,116)(946)(1,304)10,6682,31875
Pretax income21,06719,9361,88916,44413,8795,8637,1718,7016,5214,6595,40117,2835,5458,7397,3341,65315,290——
Income tax2,8042,8031,5121,9181,5211,3401,5652,5084,1037189425,3491,0282,4409426712,2681,99995
Net income18,25417,11736514,51913,0497,0679,8436,2202,3943,9204,44211,9204,4046,1686,27286112,8997,8083,275
Diluted EPS ($)7.286.740.145.715.142.783.812.320.871.411.564.071.472.002.020.285.653.631.49
Diluted shares (millions)2,5072,5412,5472,5422,5382,5412,5802,6792,7482,7872,8412,9282,9963,0763,0943*2,2732,143—

Balance sheet

Merck balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Mar 1, 2010FY2008ended Dec 31, 2008filed Jul 24, 2009FY2007ended Dec 31, 2007filed Jul 24, 2009
Cash and equivalents14,56513,2426,84112,6948,0968,0509,6767,9656,0926,5158,5247,44115,62113,45113,53110,9009,3114,3685,336
Short-term investments0447252498007748992,4067,8264,9038,2781,8652,6901,4411,3012931,118—
Total current assets43,51638,78232,16835,72230,26627,76427,48325,87524,76630,61429,75132,60535,68534,85733,18129,06428,43219,113—
Total assets136,866117,106106,675109,160105,69491,58884,39782,63787,87295,377101,67798,167105,645106,132105,128105,781112,31447,196—
Total current liabilities28,32728,42025,69424,23923,87227,32722,22022,20618,61417,20419,20118,39717,86818,34816,24515,64115,64114,319—
Long-term debt46,75034,46233,68328,74530,69025,36022,73619,80621,35324,27423,82918,69920,53916,25415,52515,48216,0953,943—
Total liabilities———————————————————
Stockholders’ equity52,60646,31337,58145,99138,18425,31725,90726,70134,33640,08844,67648,64749,76553,02054,51754,37659,05818,758—
Shares outstanding (millions)2,4722,5262,5332,5392,5282,5302,5362,5812,6962,7462,7752,8382,9413,0223,0443,0833,115——

Cash flow statement

Merck cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Mar 1, 2010FY2008ended Dec 31, 2008filed Jul 24, 2009FY2007ended Dec 31, 2007filed Jul 24, 2009
Operating cash flow16,47221,46813,00619,095—10,25313,44010,9226,45110,37612,5387,98911,65410,02212,38310,8223,3926,5726,999
Capital expenditures4,1123,3723,8634,3884,4484,4293,3692,6151,8881,6141,2831,3171,5481,9541,7231,6781,4611,2981,011
Free cash flow (CFO − capex)12,36018,0969,14314,707—5,82410,0718,3074,5638,76211,2556,67210,1068,06810,6609,1441,9315,2745,988
Depreciation and amortization——————3,6524,5194,6765,4716,3756,6916,9886,9787,4277,3812,5761,6311,988
Share repurchases5,0841,3061,34608401,2814,7809,0914,0143,4344,1867,7036,5162,5911,9211,59302,7251,430
Dividends paid8,1767,8407,4457,0126,6106,2155,6955,1725,1675,1245,1175,1705,1575,1164,6914,7343,2153,2793,307

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$30M
17 sales by 5 insiders; officers and directors $30M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$72M
35 sales by 11 insiders; officers and directors $72M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Aug 13, 2026Guindo ChirfiEVP, Access, Policy & Commsopen-market sale10,000$135.00$1M36,613Aug 13, 2026
Aug 12, 2026Zachary JenniferEVP, General Counseloption exercise41,494$117.89$5M112,391Aug 13, 2026
Aug 12, 2026Zachary JenniferEVP, General Counseloption exercise13,433$84.71$1M125,824Aug 13, 2026
Aug 12, 2026Zachary JenniferEVP, General Counselopen-market sale80,315$133.46$11M45,509Aug 13, 2026
Aug 12, 2026DeLuca Richard R.EVP&Pres, Merck Animal Heallthopen-market sale11,099$131.61$1M110,767Aug 12, 2026
Aug 12, 2026DeLuca Richard R.EVP&Pres, Merck Animal Heallthopen-market sale600$132.04$79K110,167Aug 12, 2026
Aug 11, 2026DeLuca Richard R.EVP&Pres, Merck Animal Heallthopen-market sale7,410$131.33$973K127,293Aug 12, 2026
Aug 11, 2026DeLuca Richard R.EVP&Pres, Merck Animal Heallthopen-market sale5,427$132.35$718K121,866Aug 12, 2026
Aug 10, 2026DeLuca Richard R.EVP&Pres, Merck Animal Heallthopen-market sale20,784$130.43$3M134,703Aug 12, 2026
Aug 6, 2026DeLuca Richard R.EVP&Pres, Merck Animal Heallthopen-market sale805$131.02$105K160,732Aug 10, 2026
Aug 6, 2026DeLuca Richard R.EVP&Pres, Merck Animal Heallthopen-market sale4,945$130.23$644K155,787Aug 10, 2026
Aug 6, 2026DeLuca Richard R.EVP&Pres, Merck Animal Heallthopen-market sale300$131.02$39K155,487Aug 10, 2026
Aug 6, 2026Guindo ChirfiEVP, Access, Policy & Commsopen-market sale15,000$131.00$2M46,613Aug 7, 2026
Aug 5, 2026Maraldo David R.EVP & Pres. MMDoption exercise6,311$73.73$465K24,523Aug 7, 2026
Aug 5, 2026Maraldo David R.EVP & Pres. MMDopen-market sale6,311$128.72$812K18,212Aug 7, 2026
Aug 5, 2026Maraldo David R.EVP & Pres. MMDoption exercise9,709$87.10$846K27,921Aug 7, 2026
Aug 5, 2026Maraldo David R.EVP & Pres. MMDopen-market sale9,709$128.72$1M18,212Aug 7, 2026
Aug 5, 2026Maraldo David R.EVP & Pres. MMDoption exercise2,686$84.71$228K20,898Aug 7, 2026
Aug 5, 2026Maraldo David R.EVP & Pres. MMDopen-market sale2,686$128.72$346K18,212Aug 7, 2026
Aug 5, 2026Williams David MichaelEVP,Chief Info&Digital Officeroption exercise4,600$77.62$357K36,316Aug 7, 2026
Aug 5, 2026Williams David MichaelEVP,Chief Info&Digital Officeropen-market sale4,600$128.77$592K31,716Aug 7, 2026
Aug 5, 2026Williams David MichaelEVP,Chief Info&Digital Officeroption exercise13,542$75.36$1M45,258Aug 7, 2026
Aug 5, 2026Williams David MichaelEVP,Chief Info&Digital Officeropen-market sale13,542$128.77$2M31,716Aug 7, 2026
Aug 5, 2026Williams David MichaelEVP,Chief Info&Digital Officeroption exercise34,705$73.73$3M66,421Aug 7, 2026
Aug 5, 2026Williams David MichaelEVP,Chief Info&Digital Officeropen-market sale34,705$128.77$4M31,716Aug 7, 2026

Full insider history for Merck, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held MRK in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded MRK by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$3M22,0000.00%trimmed −12.0%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Merck & Co., Inc., CIK 310158 on EDGAR
Extract generated
August 27, 2026
Withheld
4 line-years whose four quarters do not sum to the filed year: cost of revenue FY2020, opex sga FY2020, pretax income FY2020, revenue FY2020
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2016, other income FY2019
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: not filed
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/MRK.json